PHVS Pharvaris N.V.

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel, potent small-molecule bradykinin B2 receptor antagonist. PHA121 is the only oral B2-receptor antagonist in clinical development, currently under Phase 1 clinical study. Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

$37.99  -2.12 (-5.29%)
As of 02/26/2021 15:59:54 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
The Netherlands

02/04/2021
30,519,276
418,717
$1,159,427,295
0.00%
SEC Edgar Online
20-F



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
29.97
0.00
-8.94%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy